Skip to main content

Table 2 Baseline characteristics of patients in the study

From: Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study

Age (years) 43.21 ± 12.99
Sex (female/male), n (%) 47/60 (43.9/56.1)
BMI (kg/m2) 24.92 ± 5.17
PTDM, n (%) 33 (32.4)
HTN, n (%) 26 (26)
HLP, n (%) 27 (26.5)
Rejection, n (%) 31 (35.2)
Etiology of liver disease (n, %)
 HBV 19 (17.7)
 HCV 4 (3.7)
 NASH 14 (13)
 AIH 11 (10.2)
 PSC 21 (19.6)
 Cryptogenic 15 (14)
 Others 23 (21.4)
AST (IU/L) 19 (9–164)
ALT (IU/L) 22.5 (8–226)
Alk.Phos (IU/L) 200 (44–800)
Steatosis in TE (n, %) 37 (34.6)
Mean CAP (dB/m) 207.76 ± 56.84
TM6SF2 rs58542926 genotype (n, %)
 CC 77 (71.9)
 CT 28 (26.1)
 TT 2 (1.8)
PCSK9 rs505151 genotype (n, %)
 AA 54 (50.4)
 AG 50 (46.7)
 GG 3 (2.8)
PCSK7 rs2277287 genotype (n, %)
 CC 26 (24.2)
 CT 44 (41.1)
 TT 37 (34.5)
  1. BMI body mass index, PTDM post transplant diabetes mellitus, HLP hyperlipidemia, HTN hypertension, HBV hepatitis B virus, HCV hepatitis C virus, NASH non-alcoholic steatohepatitis, AIH autoimmune hepatitis, PSC primary sclerosing cholangitis, AST aspartate aminotransferase, ALT alanine aminotransferase, Alk.Phos alkaline phosphatase, TE transient elastography, TM6SF2 transmembrane 6 super family 2, PCSK9 proprotein convertase subtilisin/kexin type 9, PCSK7 proprotein convertase subtilisin/kexin type 7